Physician profile
Osiris Salcedo
NPI 1780952101
$2,153.60
in general payments reported to CMS, 2019-2025
15 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $15.00 · 2022: $1,395 · 2023: $82.18 · 2024: $162 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $1,395.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.18 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $101.31 | 2019-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $99.86 | 2024 | |
| Amgen INC. | $95.46 | 2023-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $73.86 | 2019-2020 | |
| Pfizer INC. | $61.50 | 2024-2025 | |
| Novo Nordisk INC | $40.08 | 2019 | |
| Abiomed | $35.18 | 2025 | |
| Merck Sharp & Dohme LLC | $29.56 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.68 | 2024 | Aralast |
| Xeris Pharmaceuticals, INC. | $24.59 | 2025 | Recorlev |
| Glaxosmithkline, LLC. | $24.04 | 2023 | Trelegy Ellipta |
| Genzyme Corporation | $21.96 | 2023 | |
| Shield Therapeutics INC | $16.34 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Osiris Salcedo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.